PGEN Precigen Inc: Price-to-Projected Revenue Ratio
Precigen, Inc. (PGEN) is penetrating an underserved gene therapy segment through collaborations with medical centers. The forward P/S trend illustrates market expectations, where 1.20 reflects the current value of the metric. While the company develops personalized medicines for diabetes and oncology patients, geopolitical tensions and sanctions are currently severely restricting the international registration of new treatment methods and the logistics of bioccomponents.
Summary analytical data breakdowns for Precigen Corp (PGEN)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt burden and liquidity indicators:
- business earnings and investment ratios data:
PGEN - Company Profit|Future Profit Precigen, Inc.|PGEN - Company Value to Net Income|Forward P/E Multiple Intrexon|PGEN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precigen Corp|PGEN - Operating profit before amortization|Net earnings per share (EPS TTM) Precigen|PGEN - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months precigen.com|PGEN - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Precigen, Inc.
- company sales and revenue statistics:
Comprehensive company analysis:Precigen PGEN
The indicator is calculated by continuously dividing the current market value of the share by the expected annual revenue. This metric allows for an assessment of the asset's overbought status by neutralizing the time gaps between quarterly reports. For Precigen, Inc. (PGEN), which focuses on high-risk clinical trials in gene therapy, this calculation reveals speculative valuation imbalances. By analyzing the projected P/S dynamics, an investor can promptly recognize overvaluation risks or a signal to close short positions.
Main competitors
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX - Price-to-Projected Revenue Ratio|Future Price to Revenue ADMA|Protagonist Therapeutics (PTGX) - Price-to-Projected Revenue Ratio|immunovant.com - Forward Price to Sales|KNSA (Kiniksa) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Grifols SA GRFS|Forward P/S Multiple ADPT|Forward Price-to-Revenue Multiple Celldex Corp CLDX|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|Market Cap to Expected Sales Ratio biocryst.com (BCRX)|Vera Therapeutics - Forward P/S Multiple|Projected Price to Revenue Dianthus Therapeutics Inc (DNTH)|PHVS: Forward P/S Multiple|Market Cap to Future Revenue Ratio AbCellera Corp (ABCL)|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|Market Cap to Projected Revenue PHAR (pharming.com)|Forward Price-to-Revenue Multiple NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Forward Price to Sales|Forward P/S Multiple ZBIO (Zenas Biopharma, Inc.)|Market Cap to Expected Sales Ratio Immunome Bio (IMNM)|GOSS - Price-to-Projected Revenue Ratio|KALV (kalvista.com) - Market Cap to Projected Revenue|SEPN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pieris Pharma|Forward Price-to-Revenue Multiple SVRA|Rigel Corp (RIGL) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio AnaptysBio, Inc. (ANAB)|ATXS: Future Price to Revenue|Forward P/S Multiple ENGN (enGene)|Projected Price to Revenue RAPT Therapeutics Inc.|Aerovate - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aclaris Therapeutics, Inc|Kyverna Therapeutics (KYTX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TLSA|Price-to-Projected Revenue Ratio Cabaletta Bio|Ventyx Biosciences Inc. - Future Price to Revenue|Forward P/S Multiple THTX|AVTX (Avalo Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple ELDN (Eledon Pharmaceuticals)|Forward P/S Multiple agenusbio.com AGEN|CLYM - Price-to-Projected Revenue Ratio|Forward Price to Sales ZURA (Zura Bio Ltd)|aTyr (ATYR) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Adagene Inc.|IMA (ImageneBio) - Forward P/S Multiple|Forward P/S Multiple Shattuck Therapeutics|Forward Price-to-Revenue Multiple EQ (Equillium, Inc.)|CNTB (connectbiopharm.com) - Forward Price to Sales|Forward P/S Multiple IMUX (Immunic)|Market Cap to Expected Sales Ratio Atara Biotherapeutics, Inc. (ATRA)|IFRX - Price-to-Projected Revenue Ratio|x4pharma.com (XFOR) - Forward Price-to-Revenue Multiple|adicetbio.com (ACET) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Celularity|Forward Price-to-Revenue Multiple INMB|Forward P/S Multiple Barinthus Biotherapeutics Corp|Price-to-Projected Revenue Ratio Kezar Life Sciences (KZR)|sabbiotherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Market Cap to Future Revenue Ratio|QTTB - Price-to-Projected Revenue Ratio|Future Price to Revenue GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Projected Revenue Ratio|ibioinc.com - Forward Price to Sales|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|Forward P/S Multiple BOLT|Forward Price-to-Revenue Multiple hcwbiologics.com HCWB|Forward P/S Multiple APVO (Aptevo Therapeutics Inc.)|Market Cap to Expected Sales Ratio AIM ImmunoTech, Inc. (AIM)|Aditxt Corp - Forward P/S Multiple|Projected Price to Revenue GRI Bio Inc (GRI)|XRTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Vyome Therapeutics (HIND)|Price-to-Projected Revenue Ratio Revelation Biosciences|Market Cap to Projected Revenue INDP (indaptusrx.com)|Forward Price-to-Revenue Multiple SCNI (Scinai Immunotherapeutics Ltd.)|CALI (calcimedica.com) - Forward Price to Sales|Forward P/S Multiple AFMD (Affimed N.V.)|Market Cap to Expected Sales Ratio Allakos Inc (ALLK)|HOOK - Price-to-Projected Revenue Ratio|IGMS (IGM Biosciences, Inc.) - Market Cap to Projected Revenue|ITOS: Forward P/S Multiple|Forward Price-to-Revenue Multiple Ocean Biomedical Inc|Forward Price-to-Revenue Multiple TCBP|Third Harmonic Bio Inc (THRD) - Market Cap to Expected Sales Ratio
